On 18 July 2024, Boehringer Ingelheim (BI) and GoodRx announced that Boehringer’s high and low concentration citrate-free Adalimumab-adbm products are being supplied in the US at a 92% discount from Humira® list price through GoodRx.
This follows the news in April 2024 of Alvotech’s deal with Cigna subsidiary Quallent Pharmaceuticals, and BI followed with a similar deal in May 2024.
BI’s high-concentration formulation of adalimumab, Cyltezo®, was approved in May 2024, whilst the low concentration formulation has been available since July 2023.
The 50mg/mL Cyltezo® is approved as an interchangeable biosimilar to Humira®, whilst the 100mg/mL product is not.
Alvotech and Teva’s Simlandi® was the first interchangeable high-concentration, citrate-free biosimilar to Humira® approved by FDA in February 2024. FDA has also approved high concentration formulations of Samsung Bioepis’ Hadlima™, Amgen’s Amjevita™, Sandoz’s Hyrimoz®, and Celltrion’s Yuflyma®.